Transcriptome assembly and profiling of Candida auris reveals novel insights into biofilm-mediated resistance [PDF]
, 2018 Candida auris has emerged as a significant global nosocomial pathogen. This is primarily due to its antifungal resistance profile but also its capacity to form adherent biofilm communities on a range of clinically important substrates.
Ben-Ami +63 more
core +4 more sources
Antimicrobial Agents and Chemotherapy, 2019 There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to Fusarium and Scedosporium. Manogepix (MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of ...
Sondus Alkhazraji +8 more
semanticscholar +1 more source
Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris [PDF]
, 2019 The enigmatic yeast Candida auris has emerged over the last decade and rapidly penetrated our consciousness. The global threat from this multidrug-resistant yeast has generated a call to arms from within the medical mycology community.
Kean, Ryan, Ramage, Gordon
core +2 more sources
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Antimicrobial Agents and Chemotherapy, 2018 Candida auris is an emerging multidrug-resistant yeast that has been responsible for invasive infections associated with high morbidity and mortality. C. auris strains often demonstrate high fluconazole and amphotericin B MIC values, and some strains are
C. Hager +5 more
semanticscholar +1 more source
Antifungal metabolites, their novel sources, and targets to combat drug resistance [PDF]
, 2022 Excessive antibiotic prescriptions as well as their misuse in agriculture are the main causes of antimicrobial resistance which poses a growing threat to public health. It necessitates the search for novel chemicals to combat drug resistance.
Choudhary, Megha +6 more
core +1 more source
Nine Things Genomics Can Tell Us About Candida auris [PDF]
, 2020 FUNDING RF was supported by MRC grant MR/N006364/2 and a Wellcome Trust Seed Award (215239/Z/19/Z). ACKNOWLEDGMENTS We would like to give thanks to Carolina Coelho for helpful discussions and assistance with Figure 1 and Jose Muñoz for valuable feedback ...
Childers, Delma S +2 more
core +1 more source
Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin [PDF]
, 2023 Introduction: Invasive Candida Infections (ICIs) have undergone a series of significant epidemiological, pathophysiological, and clinical changes during the last decades, with a shift toward non-albicans species, an increase in the rate of exogenous ...
De Rosa F. G. +6 more
core +8 more sources
Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia [PDF]
, 2017 Background: Innate immune responses contribute to successful resolution of bacterial pneumonia. Bolstering host defense with immunomodulators might be increasingly needed to improve outcomes in antibiotic-resistant infections.
DiNubile, Mark +4 more
core +1 more source
Molecular Mechanisms of Resistance to Antifungals in Candida albicans [PDF]
, 2021 Invasive Candidiasis (IC) presents a global mortality rate greater than 40%, occupying the fourth place worldwide as the most frequent opportunistic nosocomial disease.
Arredondo-Sánchez, Rosa Isela +6 more
core +1 more source
Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope [PDF]
, 2018 Invasive Scedosporium spp. and Lomentospora prolificans infections are an emerging threat in immunocompromised and occasionally in healthy hosts. Scedosporium spp. is intrinsically resistant to most, L. prolificans to all the antifungal drugs currently
Aurbach, Ute +27 more
core +4 more sources